Premium
[IC‐P‐195]: SPATIAL CORRESPONDENCE OF ALZHEIMER's DISEASE‐RELATED TAU PATHOLOGY AND GREY MATTER ATROPHY DISTRIBUTION WITH INTRINSIC FUNCTIONAL BRAIN NETWORKS
Author(s) -
Schöll Michael,
Grothe Michel J.,
Strandberg Olof,
Olsson Tomas,
Hägerström Douglas,
Jögi Jonas,
Smith Ruben,
Hansson Oskar
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.2570
Subject(s) - precuneus , atrophy , grey matter , neuroscience , default mode network , magnetic resonance imaging , pathology , posterior cortical atrophy , tau pathology , human brain , psychology , alzheimer's disease , functional magnetic resonance imaging , medicine , white matter , disease , dementia , radiology
Background: [F]THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). However, high uptake to brain regions with negligible concentrations of PHF constitutes an unresolved issue to be addressed. Given previously described interactions between quinolone derivatives and monoamine oxidase B (MAO-B), we tested the effects of MAO-B inhibition on [F]THK5351 brain uptake using positron emission tomography (PET) and autoradiography. Methods: 8 participants (5 mild cognitive impairment, 2 Alzheimer’s disease and 1 progressive supranuclear palsy) underwent baseline [F]AZD4694 and [F]THK5351 PET scans to quantify brain amyloid and PHF loads respectively. A second [F]THK5351 scan was performed 1 week later, 1 hour after an oral dose of 10mg selegiline. 3 out of the 8 patients also had a third [F]THK5351 scan 9-28 days after the postselegiline scan. The primary outcome measure was the standardized uptake value (SUV), calculated using tissue radioactivity concentration from 50 to 70 minutes after [F]THK5351 injection,